Content about Federal Trade Commission

March 5, 2013

The stakes are high in a case involving generic drug maker Actavis and the Federal Trade Commission that will soon go before the Supreme Court, the head of a generic drug industry lobbying group said in a conference call with reporters Tuesday.

NEW YORK — The stakes are high in a case involving generic drug maker Actavis and the Federal Trade Commission that will soon go before the Supreme Court, the head of a generic drug industry lobbying group said in a conference call with reporters Tuesday.

The case, FTC v. Actavis, will go before the high court on March 25 and may decide the future of patent settlements between branded and generic drug companies. The Generic Pharmaceutical Association filed an amicus brief with the court last week defending the settlements as beneficial to consumers.

March 1, 2013

The Supreme Court will hear arguments later this month in a case that could determine the future of many patent settlements between brand and generic drug makers.

WASHINGTON — The Supreme Court will hear arguments later this month in a case that could determine the future of many patent settlements between brand and generic drug makers.

The high court will hear arguments in the case, Federal Trade Commission v. Actavis, on March 25. The case was originally titled FTC v. Watson, but has changed since Watson Pharmaceuticals changed its name following its acquisition of Swiss generic drug maker Actavis.

February 28, 2013

The battle over "pay for delay" continues to heat up, and its resolution likely won't come until the nation's highest court decides on the legality of the practice.

The battle over "pay for delay" continues to heat up, and its resolution likely won't come until the nation's highest court decides on the legality of the practice.

February 19, 2013

The Food and Drug Administration and the Federal Trade Commission issued a number of warning letters to distributors of "unapproved medicines," noting that because each of the products identified claimed to prevent or treat the cold or flu, they need to be registered and approved by the FDA.

SILVER SPRING, Md. — The Food and Drug Administration and the Federal Trade Commission last week issued a number of warning letters to distributors of "unapproved medicines," noting that because each of the products identified claimed to prevent or treat the cold or flu, they need to be registered and approved by the FDA. And because none of the ingredients listed are in fact monographed OTC cough, cold or flu symptom relievers, those products would additionally need to be filed as "new drugs."

January 8, 2013

The Vitamin Shoppe's proposed acquisition of Super Supplements has been delayed, the company recently announced.

NORTH BERGEN, N.J. — The Vitamin Shoppe's proposed acquisition of Super Supplements has been delayed, the company recently announced. According to the company, the Federal Trade Commission had notified VSI that it is conducting an investigation into the planned acquisition, noting that the investigation will extend beyond Dec. 31, 2012.

January 3, 2013

Pfizer's generics division has launched an authorized generic drug for treating epilepsy.

PEAPACK, N.J. — Pfizer's generics division has launched an authorized generic drug for treating epilepsy.

Greenstone announced the introduction of phenytoin tablets in the 50-mg strength, an authorized generic version of Pfizer's Dilantin Infatabs.

Authorized generics are generic drugs marketed under their generic names at a reduced price, often through third-party companies under contract with the original drug's manufacturer.

December 12, 2012

Thousands of patients in Los Angeles with serious, chronic diseases could soon find themselves unable to get their drugs from community pharmacies, advocates for the pharmacies said.

NEW YORK — Thousands of patients in Los Angeles with serious, chronic diseases could soon find themselves unable to get their drugs from community pharmacies, advocates for the pharmacies said.

December 11, 2012

The Supreme Court will review settlements between branded and generic drug companies that critics say delay patients' access to cheaper drug treatments, according to published reports.

NEW YORK — The Supreme Court will review settlements between branded and generic drug companies that critics say delay patients' access to cheaper drug treatments, according to published reports.

Politico reported that the justices had agreed to hear three cases, including Federal Trade Commission v. Watson Pharmaceuticals, involving settlements between branded and generic drug companies that critics deride as "pay-for-delay" deals.

November 29, 2012

Watson Pharmaceuticals is changing its name to Actavis following its acquisition of the Swiss drug maker, Watson said.

Watson to change brand in 2013
PARSIPPANY, N.J. — Watson Pharmaceuticals is changing its name to Actavis following its acquisition of the Swiss drug maker, Watson said. Watson, whose $5.6 billion acquisition of Actavis received approval from the Federal Trade Commission in October, said it would adopt the new name starting in 2013, with plans to start a multi-year rebranding campaign and trade under a new symbol on the New York Stock Exchange.


November 16, 2012

The Federal Trade Commission has approved a deal by Valeant Pharmaceuticals International to buy a Scottsdale, Ariz.-based drug maker.

MONTREAL — The Federal Trade Commission has approved a deal by Valeant Pharmaceuticals International to buy a Scottsdale, Ariz.-based drug maker.

Valeant said the FRC had finished reviewing its planned acquisition of Medicis Pharmaceutical and allowed the waiting period required under merger and acquisition laws to terminate early.

Valeant said the deal is still subject to conditions like the approval of Medicis' stockholders, who will have a special meeting on Dec. 7. Medicis makes drugs for asthma, fungal infections and skin conditions like acne and eczema.

November 13, 2012

The American Medical Association has come out in favor of legislation to stop deals between branded and generic drug makers that critics blame for delaying entry of generics into the market, according to published reports.

NEW YORK — The American Medical Association has come out in favor of legislation to stop deals between branded and generic drug makers that critics blame for delaying entry of generics into the market, according to published reports.

Forbes reported that the AMA would support federal legislation to ban so-called "pay-for-delay" settlements. The AMA joins the Federal Trade Commission, which has strongly criticized the settlements

November 1, 2012

Watson Pharmaceuticals is changing its name to Actavis following its acquisition of the Swiss drug maker, Watson said.

 

PARSIPPANY, N.J. – Watson Pharmaceuticals is changing its name to Actavis following its acquisition of the Swiss drug maker, Watson said.

 

Watson, whose $5.6 billion acquisition of Actavis received approval from the Federal Trade Commission earlier this month, said it would adopt the new name starting in 2013, with plans to start a multi-year rebranding campaign and trade under a new symbol on the New York Stock Exchange.

 

October 22, 2012

Watson Pharmaceuticals and Actavis will have to divest rights to almost two dozen drugs as a condition for U.S. regulatory approval of their $5.6 billion merger announced earlier this year, according to regulatory documents.

NEW YORK – Watson Pharmaceuticals and Actavis will have to divest rights to almost two dozen drugs as a condition for U.S. regulatory approval of their $5.6 billion merger announced earlier this year, according to regulatory documents.

October 16, 2012

The Federal Trade Commission has voted to approve Watson Pharmaceutical's acquisition of Switzerland-based generic drug maker Actavis.

PARSIPPANY, N.J. – The Federal Trade Commission has voted to approve Watson Pharmaceutical's acquisition of Switzerland-based generic drug maker Actavis.

The unanimous vote in support of the merger follows Watson's agreement to divest a number of marketed and pipeline products to Par Pharmaceutical and Sandoz as a condition to obtaining FTC approval.

October 12, 2012

One of the most common reasons that retailers give for pet-medication programs is that pets are part of the family.

WHAT IT MEANS AND WHY IT'S IMPORTANT — One of the most common reasons that retailers give for pet-medication programs is that pets are part of the family.

As analyst Debbie Wang of investment firm Morningstar told Drug Store News in April 2012, more empty nesters and young couples putting off having children are driving increases in pet ownership, and with that comes a need for pet healthcare.

October 9, 2012

A meeting with federal officials last week indicates that pharmacists' importance in dispensing animal drugs is growing.

RHINELANDER, Wis. — A meeting with federal officials last week indicated that pharmacists' importance in dispensing animal drugs is growing.

Last Tuesday, pharmacists and veterinarians met with officials from the Federal Trade Commission in Washington, D.C., for a four-session meeting that affirmed pharmacists' increasing role, according to online pet supply company Drs. Foster and Smith.

September 20, 2012

The Council for Responsible Nutrition on Wednesday created a free, searchable compilation of all dietary supplement advertising decisions issued by the National Advertising Division since 2007, when the Dietary Supplement Advertising Review Program began.

WASHINGTON — The Council for Responsible Nutrition on Wednesday created a free, searchable compilation of all dietary supplement advertising decisions issued by the National Advertising Division since 2007, when the Dietary Supplement Advertising Review Program began.

July 17, 2012

Watson Pharmaceuticals confirmed it received a request for additional information from the Federal Trade Commission in connection with the drug maker's pending acquisition of Actavis Group.

PARSIPPANY, N.J. — Watson Pharmaceuticals confirmed it received a request for additional information from the Federal Trade Commission in connection with the drug maker's pending acquisition of Actavis Group.

July 2, 2012

Giant Food has commenced its conversion of 15 former Genuardi's stores.

CARLISLE, Pa. — Giant Food has commenced its conversion of 15 former Genuardi's stores.

The announcement follows Giant Food, an Ahold subsidiary, getting the green light from the Federal Trade Commission for its plan to acquire 15 Genuardi's stores, located in the greater Philadelphia area, from Safeway.

June 18, 2012

The Federal Trade Commission has approved Giant Food Stores' proposal to acquire 15 Genuardi's stores from Safeway.

CARLISLE, Pa. — The Federal Trade Commission has approved Giant Food Stores' proposal to acquire 15 Genuardi's stores from Safeway.

The announcement follows Giant's Jan. 5 announcement that it would acquire the Genuardi's stores, all of which are located in the greater Philadelphia market. Giant also noted that under the terms of a consent order approved by the FTC, the Genuardi's located in Newtown, Pa., will be purchased by Newtown Market and will be operated as a McCaffrey's supermarket.

May 7, 2012

The battle for public opinion and legislative sway was in full swing Monday as executives from the National Community Pharmacists Association lobbied congressional leaders regarding several pieces of "pro-patient, pro-pharmacist legislation." To counter that effort, the Pharmaceutical Care Management Association issued some marketing firepower of its own.

WASHINGTON — The battle for public opinion and legislative sway was in full swing Monday as executives from the National Community Pharmacists Association lobbied congressional leaders regarding several pieces of "pro-patient, pro-pharmacist legislation." To counter that effort, the Pharmaceutical Care Management Association issued some marketing firepower of its own.

April 27, 2012

The National Retail Federation on Thursday urged the Federal Trade Commission to move cautiously in establishing regulations for mobile payments and said any rules that are adopted should parallel those for the underlying form of payment and not be specific to the technology.

WASHINGTON — The National Retail Federation on Thursday urged the Federal Trade Commission to move cautiously in establishing regulations for mobile payments and said any rules that are adopted should parallel those for the underlying form of payment and not be specific to the technology.

April 25, 2012

The U.S. District Court for the Western District of Pennsylvania on Wednesday denied a preliminary injunction filed by pharmacy trade groups in an effort to block the looming merger between pharmacy benefit managers Express Scripts and Medco.

PITTSBURGH — The U.S. District Court for the Western District of Pennsylvania on Wednesday denied a preliminary injunction filed by pharmacy trade groups in an effort to block the merger between pharmacy benefit managers Express Scripts and Medco.

April 20, 2012

As the industry geared up for this year’s National Association of Chain Drug Stores Annual Meeting, Drug Store News talked with NACDS president and CEO Steve Anderson about the hottest issues facing pharmacy and his thoughts on the 2012 presidential election.

As the industry geared up for this year’s National Association of Chain Drug Stores Annual Meeting, Drug Store News talked with NACDS president and CEO Steve Anderson about the hottest issues facing pharmacy and his thoughts on the 2012 presidential election.

Drug Store News: What do you think will be the hot-button issues that will be top of mind at this year’s Annual Meeting?

April 11, 2012

A federal judge in Pittsburgh will rule "later" on whether to block or allow a merger between pharmacy benefit managers Medco Health Solutions and Express Scripts, and is considering a request by two trade groups seeking to keep Medco's operations and assets separate from ESI while the lawsuit is pending, according to published reports.

NEW YORK — A federal judge in Pittsburgh will rule "later" on whether to block or allow a merger between pharmacy benefit managers Medco Health Solutions and Express Scripts, and is considering a request by two trade groups seeking to keep Medco's operations and assets separate from ESI while the lawsuit is pending, according to published reports.